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Bioreductive chemotherapy plays an important role in treatment of
many human diseases including certain types of cancer (Sartorelli,
1988; Ross et al, 1994; Workman, 1994; Rauth et al, 1997). The
development of these drugs is based upon specific reductase
enzymes and the identification of tumour types that are rich in
those enzymes. In addition, it is also based on differences in
oxygen content and cellular pH between normal and tumour
tissues (Ross et al, 1994). Several quinones (e.g. mitomycin C
(MMC) and indoloquinone EO9) and dinitrophenylaziridine
CB1954 occupy a special place in bioreductive therapy because of
their tendency to undergo reductive activation by different reduc-
tases in aerobic and hypoxic conditions. MMC and its analogues
are effective against several tumour tissue types including colon,
breast and head and neck (Verweij and Pinedo, 1990).
Among the various reductases, the role of NAD(P)H:quinone
oxidoreductase1 (NQO1) in bioreductive chemotherapy was
extensively studied. Most of the studies were done for MMC.
However, NQO1 enzyme has also been demonstrated for the
activation of CB1954 (Knox et al, 1988), diaziquinone (Siegel
et al, 1990), and the indoloquinone EO9 (Workman, 1994).
Bioreductive metabolism leading to the formation of electrophilic
metabolites capable of binding with DNA to cause its damage is
the basic cause of cytotoxicity and anti-tumour activity of MMC
(Iyer and Szybalski, 1964). Several studies used dicoumarol
inhibition of NQO1 to demonstrate that NQO1 is important for the
cytotoxicity of MMC under aerobic conditions (Siegel et al, 1990;
Dulhanty and Whitmore, 1991; Marshall et al, 1991). However,
the actual involvement of NQO1 enzyme in the activation of
MMC remains controversial (Workman, 1994). Although as
mentioned earlier, there are a number of model systems where
aerobic resistance to MMC correlates with a loss of NQO1 activity
(Fitzsimmons et al, 1996), a lack of correlation was reported in the
‘Oxford’ panel of 15 cell lines (Robertson et al, 1992). More
recent data using cells expressing higher levels of cDNA-derived
NQO1 failed to demonstrate increased sensitivity to MMC, as
compared to cells of similar origin containing normal levels of
NQO1 (Powis et al, 1995; Joseph et al, 1996). The role of NQO1
in activation of MMC under hypoxic conditions is also question-
able (Workman, 1994). This is clearly evident by the observation
of high sensitivity of human colon carcinoma (BE) cells that lack
NQO1 to MMC and indoloquinone EO9 in hypoxia (Plumb and
Workman, 1994).
In this report, we present evidence to demonstrate that a unique
cytosolic enzyme distinct from NQO1 catalyses reductive activa-
tion of MMC. These include: (1) the CHO cells permanently over-
expressing cDNA-derived NQO1 failed to demonstrate higher
sensitivity to MMC, as compared to control CHO cells; and (2) the
cytosolic extracts from liver and colon of NQO1–/– mice showed
more or less similar amounts of MMC-induced DNA cross-
linking, as compared with cytosolic extracts of wild-type
(NQO1+/+) mice. Further experiments revealed that cytosolic
MMC reductase is inhibited by dicoumarol and is immunologi-
cally related to cytosolic NQO1.
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Summary Mitomycin C (MMC) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer.
Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse
bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity. However, the role of NQO1 in metabolic activation of MMC
has been disputed. In this report, we present cellular and animal models to demonstrate that NQO1 may play only a minor role in metabolic
activation of MMC. We further demonstrate that bioreductive activation of MMC is catalysed by a unique cytosolic activity which is related but
distinct from NQO1. Chinese hamster ovary (CHO) cells were developed that permanently express higher levels of cDNA-derived NQO1.
These cells showed significantly increased protection against menadione toxicity. However, they failed to demonstrate higher cytotoxicity due
to exposure to MMC under oxygen (normal air) or hypoxia, as compared to the wild-type control CHO cells. Disruption of the NQO1 gene by
homologous recombination generated NQO1–/– mice that do not express the NQO1 gene resulting in the loss of NQO1 protein and activity.
The cytosolic fractions from liver and colon tissues of NQO1–/– mice showed similar amounts of DNA cross-linking upon exposure to MMC,
as observed in NQO1+/+ mice. The unique cytosolic activity that activated MMC in cytosolic fractions of liver and colon tissues of NQO1–/–
mice was designated as cytosolic MMC reductase. This activity, like NQO1, was inhibited by dicoumarol and immunologically related to
NQO1. © 2000 Cancer Research Campaign
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Materials
The Chinese hamster ovary (CHO) cells were obtained from
American Type Culture Collection (ATCC, Rockville, MD, USA).
MMC was a gift from Bristol Myers Squibb (Princeton, NJ, USA).
Polyclonal antibodies against purified full-length NQO1 protein
was raised in rabbits in our laboratory. The NQO1 antibodies
cross-react with cytosolic NQO1 and NQO2 proteins from rodents
and human (Jaiswal et al, 1990; Shaw et al, 1991).
Development of CHO cells stably expressing high
levels of cytosolic NQO1 activity
The human NQO1 cDNA was subcloned in pED4 vector
(Kaufman et al, 1991) to generate pED4-NQO1 recombinant
plasmid. The CHO cells were grown in 5% carbon dioxide at 37°C
in Iscove’s Dulbecco’s modified essential medium (DMEM)
containing 10% fetal bovine serum, 0.1 mM hypoxanthine,
0.01 mM thymidine, 50 ml ml–1 streptomycin and 2 mM
glutathione. pED4-NQO1 plasmid DNA was linearized by diges-
tion with Nde1 and transfected in CHO cells as described previ-
ously (Shaw et al, 1991). Sixty-two hours after transfection, the
cells were washed with 1 ´ phosphate-buffered saline (PBS)
trypsinized and plated in medium deficient in thymidine and
hypoxanthine at different dilutions of 1:5, 1:10, 1:20 and 1:40. A
portion of cells were analysed for NQO1 activity by a previously
described method (Shaw et al, 1991). The cells were allowed to
grow in medium deficient in thymidine and hypoxanthine for 14
days. During this period, the medium was changed every third day.
After 14 days, the colonies were visible. They were picked and
expanded in 24-well plates. Selection of CHO cells continued in
medium containing methotrexate at concentrations of 0.02, 0.1
and 0.5 mM. All the clones selected at various stages of
methotrexate treatment were analysed for NQO1 activity. Three of
these clones CHO (NQO1-13), CHO (NQO1-38) and CHO
(NQO1-3682) expressing 13-, 38- and 3682-fold higher levels of
NQO1, as compared with wild-type control CHO cells, were
selected for further studies. The selected CHO cell clones were
grown in medium deficient in methotrexate for 4 weeks without
loss of NQO1 activity.
Cytotoxicity assays
The wild-type control CHO cells and the three CHO cell clones
expressing varying levels of cDNA-derived NQO1 were grown in
dishes without methotrexate. The various cells were treated with
different concentrations of MMC and mendione (vitamin K). The
growth/survival of cells following 3 days of exposure to drugs was
measured by procedures as described (Skehan et al, 1990; Zilfou
et al, 1995). In addition, the cytotoxicity of drugs was also deter-
mined by colony formation assay as described previously (Sakai
et al, 1995). Briefly, the CHO cells expressing different levels of
NQO1 were grown in monolayer, trypsinized and plated at a
density of 200 cells per 60-mm Petri dish in medium containing
the various concentrations of MMC. After 24 h, the medium
containing MMC was replaced with fresh medium without MMC.
The hypoxic treatment of MMC was done for 1 h. The cells were
allowed to grow for 12–15 days into colonies. The colonies were
stained and counted. The drug concentration to produce 50%
reduction in colony formation was determined.
Generation of NQO1–/– mice
We used gene targeting method to disrupt the NQO1 gene and
generated NQO1–/– mice that do not express NQO1 protein and
activity (Radjendirane et al, 1998). The development of NQO1–/–
mice was normal. The NQO1+/+ and NQO1–/– mice were bred to
generate sufficient mice for MMC sensitivity assays. The levels
of dicoumarol-sensitive cytosolic NQO1 activity in the various
tissues of wild-type (NQO1+/+) and NQO1–/– mice were
measured. The NQO1 activity (nmol of 2,6-dichlorophenolin-
dophenol reduced min–1 mg–1 cytosolic protein) dropped from
515.3  ± 37.2 in colon of wild-type mice to zero levels in NQO1–/–
mice. The NQO1 activity also dropped significantly (> 85%;
NQO1+/+, 136.5 ± 10.2; NQO1–/–, 19.6 ± 4.1) in liver. The
residual amounts of NQO1 activity observed in livers of NQO1-
null mice is due to NQO1 related protein(s) rather than NQO1
(Radjendirane et al, 1998). This is because NQO1 protein was
absent in livers of NQO1–/– mice as determined by Western
analysis (Radjendirane et al, 1998).
Metabolic activation of MMC in cytosolic fractions from
wild-type (NQO1+/+) and NQO1–/– mice as determined
by DNA cross-linking
The cytosolic fractions from liver and colon tissues of wild-type
(NQO1+/+) and NQO1–/– mice were prepared by standard
procedures. These cytosolic fractions were absolutely free of
microsomal contamination as no activity of microsomal-specific
enzyme NADPH: cytochrome P450 reductase was detected in the
various cytosolic fractions (data not shown). The cytosolic frac-
tions from wild-type (NQO1+/+) mice containing one unit of
NQO1 activity (equivalent to one mmol of 2,6-dichloropheno-
indophenol reduced in 1 min) and similar amounts of cytosolic
proteins from NQO1–/– mice were incubated with 23 base pair of
double-stranded oligonucleotides containing MMC binding site
and DNA cross-linking assays performed by procedure as
described (Joseph et al, 1996). The nucleotide sequence of the
23 base pair oligonucleotide was 5¢-CTACATCGTGTCATG-
CACAGGAT-3¢. The complementary strands were mixed in equal
amounts and annealed by heating to 70°C and slowly cooling to
room temperature. The 3¢-end of the top strand was selectively
labelled by Klenow enzyme in the presence of [a-32P]dCTP. The
labelled duplexes were purified on a 15% polyacrylamide gel and
used for incubation with the cytosolic extracts for cross-linking by
activated MMC. The incubation mixture included 100 mM phos-
phate buffer (pH 5.8), cytosolic protein, 1 mM NADH, 100 mM
MMC, 5 mM FAD, 0.01% Tween-20 and 0.18 mg bovine serum
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Table 1 Mitomycin C-induced cytotoxicity of CHO and CHO-NQO1 cells as
determined by colony formation assay
NQO1 Mitomycin C
S. No. Cells activity IC50
1 CHO (W) 0.02 ± 0.01 75 ± 4
2 CHO-NQ01-(13) 0.27 ± 0.03 71 ± 5
3 CHO-NQ01-(38) 11.54 ± 0.10 73 ± 4
4 CHO-NQO1-(3682) 73.65 ± 3.10 59 ± 2
NQO1 activity, mmol of 2,6-dichlorophenolindophenol reduced min–1 mg–1
protein. Mitomycin C (MMC) IC50 mmol of MMC required to kill 50% of cells in
cytotoxicity assays as determined by the procedures as described (Sakai
et al, 1995). albumin. Reactions were terminated by the addition of ethanol,
and the precipitated oligomer duplexes were denatured by heating
at 95°C for 5 min in DNA sequencing dye containing formamide.
The samples were analysed on a 15% denaturing polyacrylamide
gel, and cross-linked and unmodified oligomers were detected by
autoradiography.
Further characterization of the unique cytosolic activity
We used polyclonal antibodies against full-length NQO1 protein in
DNA cross-linking assays to determine if the unique cytosolic
activity that activates MMC leading to DNA cross-linking is
related to NQO1. The cytosolic extracts from human colon
carcinoma (HT29) cells containing one unit of NQO1 activity
(reduction of one mmol of 2,6-dichlorophenolindophenol in 1 min)
were incubated with either pre-immune serum or antibodies
against NQO1 in various concentrations for antigen/antibody reac-
tions. Half of the incubation mixture was analysed for NQO1
activity (2,6-dichlorophenolindophenol reduction) and another
half analysed for its capacity to catalyse MMC induced DNA
cross-linking. Similar experiments were also performed with colon
cytosolic extracts of NQO1+/+ and NQO1–/– mice.
RESULTS
The transfection of CHO cells with pED4-NQO1 plasmid resulted
in generation of a series of CHO cell clones that permanently
express higher levels of NQO1 (Table 1). Three of these clones
A unique cytosolic mitomycin C reductase 1307
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Figure 1 Sensitivity of CHO cells expressing different levels of cDNA-derived NQO1 to MMC and menadione. The wild-type CHO (W) cells and CHO cells
permanently expressing higher levels of cDNA-derived NQO1 were grown in dishes and treated with MMC or menadione. The growth/survival of cells following
three days of exposure to drugs was measured. (A) Treatment with MMC; (B) treatment with MMC in hypoxia; (C) treatment with menadione. All values are
mean of three independent experiments
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02 0 6 0 40 80 100 120expressing 13-, 38- and 3682-fold higher levels of NQO1 were
used for MMC cytotoxicity assays. Two methods were used to
assess the cytotoxicity of the various CHO cell clones to MMC.
These included: (1) inhibition of growth of CHO cells as deter-
mined by SRB colourimetric assay, and (2) colony formation. The
results are shown in Figure 1 and Table 1. The CHO cells
expressing higher levels of NQO1 showed more or less similar
survival rate as wild-type control upon treatment with different
concentrations of MMC (Figure 1A). Similar results were
observed upon treatment of CHO cells with MMC in hypoxia
(Figure 1B). However, replacement of MMC with menadione
showed significant protection of CHO cells expressing higher
levels of NQO1, as compared with wild-type control cells (Figure
1C). The results also indicated absence of a positive correlation
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Figure 3 (A) Comparison of per cent inhibition of mitomycin C induced DNA cross-linking and cytosolic NQO1 activity from human colon carcinoma HT29 cells
under similar conditions. The cytosolic extracts from HT29 cells containing one unit of NQO1 activity (2,6-dichlorophenolindophenol) were treated with either
pre-immune serum (10 ml) or anti-NQO1 serum (in different concentrations) for 1 h at 4°C. Half of the incubation mixture was analysed for NQO1 (2,6-
dichlophenolindophenol reduction) and another half analysed for its capacity to catalyse mitomycin C (MMC) induced DNA cross-linking. The cross-linked bands
were cut out and counted for per cent inhibition. The inhibition of NQO1 activity and MMC induced DNA cross-linking by anti-NQO1 antibodies are represented
as per cent of control results obtained with cytosolic extracts treated with pre-immune serum. The data are presented as mean of three independent
experiments. (B) Inhibition of MMC-induced DNA cross-linking by polyclonal antibodies against purified human NQO1 (NQO1 antiserum). The cytosolic extract
from HT29 cells containing one unit of NQO1 activity (2,6-dichlorophenolindophenol) was treated with either pre-immune serum (10 ml) or anti-NQO1 serum
(in different concentrations) for 1 h at 4°C and analysed for their capacity to catalyse mitomycin C (MMC) induced DNA cross-linking
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Figure 2 Mitomycin C-induced inter-strand DNA cross-linking. (A) Cytosolic extracts from wild-type (NQO1+/+) and NQO1–/– mice were incubated with
32P-labelled 23 base pairs of oligonucleotides containing the mitomycin C binding site and 100 mM mitomycin C in absence and presence of dicoumarol by
procedures as described in Materials and Methods. The reaction was stopped with DNA sequencing dye containing formamide, heated to denature the DNA
and separated on 15% denaturing polyacrylamide gel. The gel was dried and autoradiographed. –D, No dicoumarol; +D, 10 mM dicoumarol. (B) The spots
containing cross-linked oligonucleotides were cut out and counted. The results are presented as mean ± s.e.m. of CPM from three independent experimentsbetween NQO1 levels in CHO cells and IC50 of MMC as deter-
mined by colony formation assays (Table 1). The 3682-fold
increase in NQO1 activity in CHO cells resulted only in less than
twofold increase in sensitivity of these cells to MMC (Table 1).
MMC-induced inter-strand DNA cross-linking was observed
with cytosolic extracts from both wild-type (NQO1+/+) and
NQO1–/– mice tissues (Figure 2 A and B). However, the amount
of DNA cross-linking was slightly lower in case of NQO1–/– mice
tissues as compared to NQO1+/+ mice. This reduction in DNA
cross-linking was no more than 15% of wild-type. The MMC-
induced DNA cross-linking in wild-type as well as NQO1–/–
tissues was inhibited by dicoumarol (Figure 2).
The results of antibody inhibition are shown in Figures 3 and 4.
The antibodies inhibited both NQO1 activity and MMC-induced
DNA cross-linking in human colon carcinoma (HT29) cells and
wild-type (NQO1+/+) and knock out (NQO1–/–) mice. However,
the inhibition kinetics of NQO1 activity was significantly different
than that of MMC reductase-induced DNA cross-linking. The
2.5 ml of NQO1 antibodies inhibited 5.5% of NQO1 activity in
HT29 cells, as compared to 43% inhibition of MMC-induced
DNA cross-linking (Figure 3). Similarly, 10 ml of NQO1 anti-
bodies inhibited 100% of MMC-induced DNA cross-linking, as
compared to only 41% inhibition of the NQO1 activity in HT29
cells (Figure 3). Similar results were also observed with cytosolic
extracts from colon of NQO1+/+ mice (Figure 4A). Therefore, the
NQO1 antiserum inhibited MMC-induced DNA cross-linking
more efficiently than NQO1 activity in both HT29 cells and
NQO1+/+ mice. The antibodies against NQO1 also inhibited
MMC induced DNA cross-linking in NQO1 deficient (NQO1–/–)
mice colon (Figure 4B).
DISCUSSION
Bioreductive chemotherapy may be the most successful treatment
for certain types of cancer (Sartorelli, 1988; Ross et al, 1994;
Workman, 1994; Rauth et al, 1997). This is because it is based on
differences between normal and tumour tissues in enzyme levels,
oxygen content and pH. The enzymes which are expressed at
higher levels in tumours may activate the drugs for killing the
tumour cells. However, similar activation in normal cells may be at
lower levels which can be detoxified. Therefore, effective dosage
of drugs could be administered with drastic damage to tumour
cells and less or no toxicity to normal cells. In addition, the
existence of hypoxic regions is a major problem in radiation
therapy, as oxygen is a radiation sensitizer. Therefore, hypoxic
parts of the tumours often survive radiation treatment, and may be
centre for a recurrent tumour. Bioreductive agents such as MMC
may be more active in these hypoxic regions of the tumours
(Kennedy et al, 1980; Stratford and Stephens, 1989). The adminis-
tration of such bioreductive agents as adjuvant to radiation may
be favourable for killing solid tumour cells. Identification of
enzyme(s) that metabolically activate anti-tumour drugs like
MMC is one step forward in this direction.
In this report, we studied the role of NQO1 and other cytosolic
enzyme(s) in metabolic activation of MMC. The results revealed
that cytosolic NQO1 plays an insignificant role in metabolic acti-
vation of MMC. The CHO cells stably expressing higher levels of
cDNA-derived NQO1 did not demonstrate increased cytotoxicity
upon exposure to MMC. This is in agreement with the earlier
report by Gustafson et al (1996). In addition, the loss of NQO1 due
to disruption of NQO1 gene did not lead to a significant difference
in sensitivity of NQO1–/– mice to MMC, as compared with
wild-type (NQO1+/+) mice. Both wild-type (NQO1+/+) and
NQO1–/– mice showed more or less similar response to MMC
exposure. Furthermore, the cytosolic fractions from liver and
colon of NQO1–/– mice deficient in NQO1 protein/activity
catalysed high affinity reductive activation of MMC which led to
inter-strand DNA cross-linking. The small amount of differences
between wild-type (NQO1+/+) and NQO1–/– mice may be due to
experimental variations or due to very low affinity of NQO1 for
MMC.
The results on MMC-induced DNA cross-linking also revealed
that cytosolic fractions of wild-type (NQO1+/+) and NQO1–/–
mice contain an activity that catalysed metabolic activation of
MMC which led to DNA cross-linking. This activity is designated
A unique cytosolic mitomycin C reductase 1309
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Figure 4 Inhibition of mitomycin C-induced DNA cross-linking and cytosolic
NQO1 activity from wild-type (NQO1+/+) and knock out (NQO1–/–) mice
colon. The cytosolic extracts from colon of wild-type and NQO1–/– mice were
treated with either pre-immune serum (10 ml) or with the various
concentrations of anti-NQO1 serum for 1 h at 4°C and analysed for
mitomycin C (MMC) induced DNA cross-linking. The data are mean ± of
three independent experimentsas cytosolic MMC reductase. The cytosolic MMC reductase
activity was inhibited by low concentrations of dicoumarol, an
inhibitor of NQO1. This indicated that cytosolic MMC reductase
activity may be related to NQO1. Further experiments using poly-
clonal antibodies against full-length NQO1 protein confirmed this.
The NQO1 antibodies inhibited both NQO1 activity catalysed
reduction of 2,6-dichlorophenolindophenol and cytosolic MMC
reductase activity catalysed MMC-induced DNA cross-linking.
However, NQO1 antibodies were more effective in inhibiting the
MMC-induced DNA cross-linking, as compared to reduction of
2,6-dichlorophenolindophenol. This may be due to lower concen-
tration of MMC reductase activity as compared to the NQO1
activity. It is for this reason that 10 ml of NQO1 antiserum
inhibited 100% of MMC-induced DNA cross-linking, as
compared to 41% inhibition of NQO1 activity.
The MMC reductase activity is expected to be a new member of
NQO gene family. Four gene loci encode for the various members
of the NQO gene family (Jaiswal, 1988). Two of these loci (NQO1
and NQO2) have been cloned and sequenced (Jaiswal et al, 1988,
1990). NQO2 is a second member of the NQO gene family that
requires NRH instead of NAD(P)H as a cofactor (Wu et al, 1997).
MMC reductase activity may not be due to NQO2 because it
requires NAD(P)H and not NRH as cofactor (Joseph et al, 1996).
Much of the literature suggests that cytosolic NQO1 and NQO2
protect cells against quinone-induced redox cycling and oxidative
stress (Riley and Workman, 1992; Talalay et al, 1995). This is
supported by observations in the present report that cytosolic
NQO1 protected CHO cells against menadione while remaining
more or less insensitive to MMC cytotoxicity. Based on the
present results, we hypothesize that NQO1 may play no, or an
insignificant, role in the activation of MMC but may exclusively
protect cells against redox cycling and oxidative stress. NQO1–/–
mice represent a valuable tool to confirm this hypothesis using
other drugs such as CB1954 and EO9. We further hypothesize that
MMC reductase catalyses metabolic activation of MMC and other
drugs and xenobiotics containing quinone structures.
In summary, we used cellular and NQO1–/– mice models to
demonstrate that cytosolic NQO1 may not activate MMC. We
have characterized a unique cytosolic (MMC reductase) activity
that catalyses metabolic activation of MMC which led to DNA
cross-linking. This activity is distinct from NQO1 but related to
NQO1. Purification and cloning of MMC reductase activity
should reveal further information on this protein and its role in
bioreductive drugs activation.
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